Sort
15,273 grants matching “antimicrobial resistance”
Non-competitive proteasome inhibitors to treat chronic, drug-resistant tuberculosis
$180,825Robert B Abramovitch · Michigan State University · R21 · FY2016 · AI
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy
$180,807Frank H. Ebetino · Biovinc, Llc · R43 · FY2016 · AI
Novel Diagnostics to Improve Antimicrobial Stewardship for Acute Respiratory Tract Infections in Resource-Limited Settings
$180,777Gayani Tillekeratne · Duke University · K23 · FY2020 · AI
Polyamine Modulation of Goncoccal Virulence
$180,762William Maurice Shafer · Emory University · R21 · FY2013 · AI
Mechanisms of resistance against the human group IIA secreted phospholipase A2 in Group B Streptococcus
$180,759Natalia Korotkova · University Of Kentucky · R21 · FY2021 · AI
Mechanisms of Enteric Burkholderia psuedomallei infection
$180,712Steven W. Dow · Colorado State University · R21 · FY2011 · AI
Washington State Public Health Laboratories NARMS Cooperative Agreement Program Application 2025-2026. Retail Meat and Seafood Surveillance.
$180,677Brian Hiatt · Washington State Department Of Health · U01 · FY2025 · FD
Evaluating the Bilayer-Couple Model of Outer Membrane Vesicle Biogenesis Using Novel Asymmetric Membrane Templates
$180,550Jeffrey Schertzer · State University Of Ny,Binghamton · R21 · FY2017 · AI
ANTIMICROBIALS AGAINST CHLAMYDIA AND GC INFECTION: IN VITRO STUDIES
$180,480Children'S Hospital Med Ctr (Cincinnati) · P01 · FY2002 · AI
ANTIMICROBIALS AGAINST CHLAMYDIA AND GC INFECTION: IN VITRO STUDIES
$180,480Children'S Hospital Med Ctr (Cincinnati) · P01 · FY2001 · AI
Caspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasis
$180,438Ryan K Shields · University Of Pittsburgh At Pittsburgh · K08 · FY2017 · AI
Mechanisms of Chronic Inflammation in Periodontitis
$180,359Niki Moutsopoulos · National Institute Of Dental & Craniofacial Research · ZIA · FY2011 · DE
Enzyme-Powered Self-Propelled DNA Nanoparticles for Disruption and Antibiotic Delivery in Topical Biofilms
$180,247Jeffrey Lawrence Moran · George Mason University · R21 · FY2022 · EB
Glyco-therapeutics for Treating Persistent S. aureus Infections of Skin and Soft Tissue
$180,185Andrea Marie Kasko · University Of California Los Angeles · R21 · FY2016 · AI
Enhancing the Capacity and Capability of Human Food and Environmental Testing Laboratory at the Texas Department of State Health Services: Overall
$180,151Susan Tanksley · Texas State Dept Of Health Services · U19 · FY2021 · FD
Development of Staphylococcalcidal Human Peptides
$180,127William Maurice Shafer · Emory University · R01 · FY2008 · AI
Feasibility of Nanopore Whole Genome Sequencing in a Public Health Laboratory
$180,038Pascal Lapierre · Wadsworth Center · R21 · FY2018 · AI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
$180,005Anthony D Harris · University Of Maryland Baltimore · K24 · FY2009 · AI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
$180,005Anthony D Harris · University Of Maryland Baltimore · K24 · FY2011 · AI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
$180,005Anthony D Harris · University Of Maryland Baltimore · K24 · FY2013 · AI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
$180,005Anthony D Harris · University Of Maryland Baltimore · K24 · FY2010 · AI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
$180,005Anthony D Harris · University Of Maryland Baltimore · K24 · FY2012 · AI
Pennsylvania Surveillance for Antimicrobial Resistant-enteric Bacteria in Retail Food
$180,000Nkuchia Mugambi M'ikanatha · Pennsylvania State Dept Of Health · U01 · FY2023 · FD
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** BOVINE MASTITIS IS A CONSTANT PROBLEM IN THE DAIRY INDUSTRY. MILK QUALITY IS AFFECTED, PRODUCTION IS REDUCED, AND ANTIBIOTICS ARE NEEDED FOR TREATMENT WHEN DAIRY COWS ARE AFFECTED BY MASTITIS. ONE OF THE MOST PREVALENT MASTITIS CAUSING BACTERIA IS STAPHYLOCOCCUS AUREUS (S. AUREUS). A POSSIBLE ALTERNATIVE TO ANTIBIOTICS IS THE USE OF BACTERIOPHAGES (PHAGES), WHICH ARE VIRUSES THAT ONLY INFECT BACTERIA. A MAJOR LIMITATION FOR PHAGES TO BE USED AS A TREATMENT FOR BOVINE MASTITIS IS WHEY PROTEIN'S ANTIVIRAL ACTIVITY. THE OVERALL GOAL IS TO INCREASE BACTERIOPHAGE (PHAGE) INFECTIVITY, THUS INCREASING ITS THERAPEUTIC POTENTIAL, OF MASTITIS CAUSING S. AUREUS BY REDUCING ITS INTERACTION WITH MILK ANTIVIRAL MECHANISMS. WE WILL DEVELOP A CELL-FREE TRANSCRIPTION-TRANSLATION (TXTL) SYSTEM DERIVED FROM STAPHYLOCOCCUS AUREUS. THE TXTL SYSTEM DOES NOT PRODUCE ENDOTOXINS OR EXOTOXINS DURING PHAGE PRODUCTION, WHICH IS A MAJOR PROBLEM IN THE CURRENT IN VIVO METHOD OF PHAGE PRODUCTION. IT WILL BE USED TO PRODUCE GREEN FLORESCENT PROTEIN AND WHOLE PHAGES FROM CIRCULARIZED PLASMID DNA. MILK WHEY PROTEIN ANTIVIRAL ACTIVITY IS A HINDRANCE TO PHAGE TREATMENT FOR MASTITIS. WE WILL BE USING THE CRISPR-CAS9 ENGINEERING METHOD TO GENETICALLY MODIFY THE SURFACE OF PHAGE CAPSIDS TO OBTAIN THE POLYMER POLYETHYLENE GLYCOL (PEG) TO CONCEAL THE PHAGE FROM THE ANTIVIRAL ACTIVITY IN RAW MILK LONG ENOUGH TO ELIMINATE S. AUREUS CONTAMINATION.THE RESULTS OF THIS PROJECT WILL BE INSTRUMENTAL IN ADVANCING THE USE OF PHAGES AS AN ANTIMICROBIAL THERAPY IN ANIMAL HUSBANDRY. THE TXTL SYSTEM WILL INCREASE THE SPEED IN WHICH WE CAN PRODUCE AND EVALUATE VIRULENT PHAGES FOR THE USE OF TREATMENT. THE ENGINEERED PHAGES FOR THE TREATMENT OF S. AUREUS IN RAW MILK SAMPLES WILL BRING US ONE STEP CLOSER TO REDUCING THE USE OF ANTIBIOTICS IN THE USE OF TREATING INFECTIONS IN THE DAIRY INDUSTRY AND REDUCE THE SPREAD OF ANTIMICROBIAL RESISTANT BACTERIA.
$180,000Cornell University · · FY2023 · National Institute of Food and Agriculture
Monitoring antimicrobial resistance (AMR) in enteric pathogens isolated from retail meats and seafoods in North Carolina
$180,000Siddhartha Thakur · North Carolina State University Raleigh · U01 · FY2022 · FD